Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| Marina Biotech, Inc. (NASDAQ: MRNA) | Delayed: 202.63 -43.18 (17.57%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $245.81 | 52 Week High | $0.52 | |||
| Open | $240.13 | 52 Week Low | $0.08 | |||
| Day High | $241.26 | P/E | N/A | |||
| Day Low | $180.80 | EPS | $-3.80 | |||
| Volume | 49,957,986 | |||||
